EUVIMEDEUVIMED entdecken
Crossref

Effectiveness of biologic therapies in children with palmoplantar plaque psoriasis: An analysis of real‐life data from the BiPe cohorts

Bochra Hanafi, Alain Beauchet, Vito Di Lernia, Audrey Lasek, Maëlla Severino-Freire, Sébastien Barbarot iD, Smail Hadj-Rabia, Alice Phan, Anne-Claire Bursztejn, Annabel Maruani, Guillaume Chaby, Nathalie Quiles-Tsimaratos und 5 weitere

Pediatric Dermatology · 2023

DOI: 10.1111/pde.15393 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Pediatric Dermatology, 2023. Verfasst von Bochra Hanafi und 16 weiteren Autor:innen. Beteiligte Einrichtung: Dermatology Department, Hôpital Victor Dupouy, Argenteuil, France. Hauptthemen laut MEDLINE: Psoriasis, Biological Products. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 20 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Palmoplantar plaque psoriasis is a frequent clinical subtype of childhood psoriasis. This study evaluated the effectiveness of biologic therapies in children with palmoplantar plaque psoriasis using data from the two Biological treatments for Pediatric Psoriasis (BiPe) cohorts.

Methods

Data for all 170 patients included in the BiPe cohorts were analyzed. Data on the effectiveness (PGA, PASI between baseline and 3 months of treatment) of biologic therapies were then compared between children with palmoplantar plaque psoriasis ( n = 20) and those with generalized plaque psoriasis ( n = 136). Clinical and demographic data were also analyzed.

Results

Children in the palmoplantar group were more likely to be male ( p = .04), with an earlier age of psoriasis onset ( p < .001), and more frequent nail involvement ( p < .001). After 3 months of biologic treatment, mean PGA scores were higher in the palmoplantar group than in the generalized plaque psoriasis group ( p = .004). In the palmoplantar group, continuation rates were higher for adalimumab than for etanercept or ustekinumab ( p = .01). Primary inefficacy was a more frequent reason for stopping biologic therapies in the palmoplantar group ( p = .01), and disease remission was less frequent ( p = .05). Combined systemic and biologic therapies were more frequently used in palmoplantar plaque psoriasis ( p < .001).

Conclusions

This study demonstrated the treatment‐resistant nature of palmoplantar plaque psoriasis and indicated that adalimumab could be the most effective biologic treatment. Larger studies are needed to allow therapeutic algorithms for palmoplantar plaque psoriasis to be proposed in pediatric psoriasis management guidelines.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

PsoriasisBiological ProductsHumansMaleChildFemaleAdalimumabEtanerceptUstekinumabBiological TherapyTreatment OutcomeSeverity of Illness Index

Stichwörter der Autor:innen

biologic therapieschildren palmoplantar plaquepsoriasispsoriasisadolescents

Substanzen

AdalimumabEtanerceptUstekinumabBiological Products

Autor:innen und Institutionen

  • Dermatology Department, Hôpital Victor Dupouy, Argenteuil, France.
  • Department of Public Health, Hôpital Raymond Poincaré, Garches, France.
  • Dermatology Unit, Arcispedale S. Maria Nuova IRCCS, Reggio Emilia, Italy.
  • Dermatology Department, Hôpital Saint Vincent de Paul, Université Catholique de Lille, Lille, France.
  • Dermatology Department, Centre de référence des maladies rares de la peau et des muqueuses, Hôpital Larrey, Toulouse, France.
  • Dermatology Department, Centre Hospitalier Universitaire de Nantes, Nantes, France.

ORCID-Profile: Sébastien Barbarot, Céline Phan, Emmanuel Mahé

Zitieren

APA

Hanafi, B., Beauchet, A., Di Lernia, V., Lasek, A., Severino-Freire, M., Barbarot, S., Hadj-Rabia, S., Phan, A., Bursztejn, A. C., Maruani, A., Chaby, G., Quiles-Tsimaratos, N., Phan, C., Zitouni, J., Mazereeuw-Hautier, J., Mahé, E., & Groupe de Recherche sur le Psoriasis (GrPso) of the Société Française de Dermatologie (SFD), Groupe de Recherche de la Société Française de Dermatologie Pédiat… (2023). Effectiveness of biologic therapies in children with palmoplantar plaque psoriasis: An analysis of real‐life data from the BiPe cohorts. Pediatric Dermatology. https://doi.org/10.1111/pde.15393

Vancouver

Hanafi B, Beauchet A, Di Lernia V, Lasek A, Severino-Freire M, Barbarot S, et al. Effectiveness of biologic therapies in children with palmoplantar plaque psoriasis: An analysis of real‐life data from the BiPe cohorts. Pediatric Dermatology. 2023. doi:10.1111/pde.15393

BibTeX
@article{Hanafi2023,
  author = {Hanafi, Bochra and Beauchet, Alain and Di Lernia, Vito and Lasek, Audrey and Severino-Freire, Maëlla and Barbarot, Sébastien and Hadj-Rabia, Smail and Phan, Alice and Bursztejn, Anne-Claire and Maruani, Annabel and Chaby, Guillaume and Quiles-Tsimaratos, Nathalie and Phan, Céline and Zitouni, Jinane and Mazereeuw-Hautier, Juliette and Mahé, Emmanuel and Groupe de Recherche sur le Psoriasis (GrPso) of the Société Française de Dermatologie (SFD), Groupe de Recherche de la Société Française de Dermatologie Pédiat…, Groupe de Recherche sur le Psoriasis (GrPso) of the Société Française de Dermatologie (SFD), Groupe de Recherche de la Société Française de Dermatologie Pédiat…},
  title = {Effectiveness of biologic therapies in children with palmoplantar plaque psoriasis: An analysis of real‐life data from the BiPe cohorts},
  journal = {Pediatric Dermatology},
  year = {2023},
  doi = {10.1111/pde.15393}
}
Kostenlos starten →